Pro Tip: Learn how to use HBI Alerts to follow your favorite topics

Laboratory Services

 

Poland’s private healthcare poised for growth as Diagnostyka plans IPO

Diagnostyka, Poland's largest private diagnostic laboratory provider, plans to list on the Warsaw Stock Exchange, hoping to achieve a $1.2 billion valuation. The IPO will involve the sale of shares by private equity firm MidEuropa, which currently backs Diagnostyka, holding a 47.83% stake. Diagnostyka’s founders, key management, and board members will retain their shares, and the company will not issue new ones. A portion of the offering, between 5 - 10%, will be allocated to retail investors, according to a press release.
January 17, 2025

FREE BLOG ‘Scaling Smart’ — HBI webinar explores how diagnostic providers are applying AI and other technologies to address growing service demand

This week saw the latest event in HBI’s webinar series, “Scaling smart: how providers are leveraging new technologies for better diagnostic delivery”.   The background to the event The purpose of the webinar was to explore the role that new digital tools, and artificial intelligence (AI) in particular, are playing in helping diagnostic providers to […]
November 28, 2024

Affidea acquires Sermesa polyclinics in Valencia

Affidea, the pan-European provider of community based clinics, advanced diagnostics, and specialist services, has announced the acquisition of Sermesa polyclinics, a well-established healthcare provider in Valencia, Spain. The acquisition is intended to strengthen and expand Affidea’s outpatient and diagnostic services presence throughout Spain, as part of its wider strategy. 
November 6, 2024

Synlab sells Spanish division to Eurofins as part of long term divestment strategy

Pan-European diagnostic labs group Synlab is continuing to divest divisions of its business located in less profitable markets to divert resources towards more profitable markets. It is selling its Spanish division to Eurofins, a major listed multinational labs group, and is also attempting to sell its Romanian division.
November 1, 2024

Preparing for the 2025 healthcare investment landscape — in conversation with Sharon Lamb, Partner at McDermott, Will & Emery

As the healthcare and life sciences sector emerges from a period of consolidation and slower deal activity, investors are eyeing 2025 with cautious optimism. HPE Europe, a conference hosted by multinational law firm McDermott, Will & Emery (MWE), convened in London this autumn to explore key investment themes and strategies for the year ahead, with HBI in attendance.
October 31, 2024

Spire’s revenue surge hints at rising private sector opportunities delivering NHS services

On September 12, Spire Healthcare, one of the UK’s top for-profit private hospital groups, reported a rise in revenues and profits. The company stated that this surge was partly driven by increased NHS outsourcing and higher private insurance uptake among working-age individuals.  The hospital’s pre-tax profits rose approximately 12% to £23 million in the first half of the year, with revenues increasing about 13% to £763 million. Spire expects annual underlying profits to range between £255 million and £275 million, having already achieved £130.6 million in the first six months.
September 20, 2024

Brookfield Asset Management takeover of Grifols continues to progress with new debt financing move

The anticipated Brookfield Asset Management takeover of Catalonia’s Grifols has gathered fresh momentum, with the firm reportedly in talks with banks to secure approximately €9.5 billion in debt financing towards the deal, according to Bloomberg sources.  The Canadian investment firm is exploring the acquisition in partnership with the Grifols family, who hold a ~30% stake […]
August 23, 2024

How CRISPR and HiBiT can accelerate drug discovery

CRISPR has been called one of the most exciting developments in genetic engineering. It is opening up new possibilities in medicine, particularly for discovering new types of drugs for genetic diseases and new ways of repairing and replacing organs and tissue in regenerative medicine. In an interview with HBI, Philip Hargreaves, Director of Strategic Marketing & Business Development at Promega UK, the UK  branch of US biotech company Promega, spoke about how CRISPR, when combined with Promega’s innovative HiBiT technology, can accelerate the drug discovery process.
August 14, 2024
Older posts
Newer posts

Our Services

Company

Resources

Log in
Register
Log in
Register

Our Services

Company

Resources

Find Us